Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Annovis Bio Inc (ANVS)

Annovis Bio Inc (ANVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 73,312
  • Shares Outstanding, K 8,164
  • Annual Sales, $ 0 K
  • Annual Income, $ -14,490 K
  • 60-Month Beta 2.11
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.74
Trade ANVS with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.34
  • Growth Rate Est. (year over year) +293,923.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.39 +3.33%
on 05/12/22
12.23 -29.16%
on 04/26/22
-3.13 (-26.51%)
since 04/25/22
3-Month
8.39 +3.33%
on 05/12/22
14.89 -41.81%
on 04/05/22
-5.79 (-40.04%)
since 02/25/22
52-Week
8.39 +3.33%
on 05/12/22
132.00 -93.44%
on 07/23/21
-40.14 (-82.25%)
since 05/25/21

Most Recent Stories

More News
Q4 Investor Summit Small Cap & Micro Cap Conference To Offer Opportunity to Meet with C-level Management of 90+ Companies

Small and Micro-cap investors are invited to attend the Q4 Investor Summit being held on November 16-17, 2021. The event is organized by the Investor Summit Group, recognised as a highly reputed brand...

AZ.TO : 6.19 (unch)
AAZZF : 10.8545 (+0.13%)
ACST : 0.9158 (+0.68%)
ATNM : 5.47 (-1.80%)
ADCO.TO : 0.2600 (-5.45%)
ADCOF : 0.2137 (-7.09%)
ALIM : 5.94 (+0.68%)
ACOGF : 0.5131 (-12.74%)
AMST : 0.6300 (+2.21%)
ANVS : 8.85 (+2.79%)
ANPC : 0.3050 (-4.69%)
ARC : 2.92 (unch)
SHAREHOLDER ALERT: Robbins LLP Investigates Annovis Bio, Inc. (ANVS) for Misleading Shareholders

Shareholder rights law firm Robbins LLP is investigating Annovis Bio, Inc. (NYSE: ANVS) to determine whether certain Annovis officers and directors violated the Securities Exchange Act of 1934. Annovis...

ANVS : 8.85 (+2.79%)
ANNOVIS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Annovis Bio, Inc. and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Annovis Bio, Inc. (“Annovis” or the “Company”)...

ANVS : 8.85 (+2.79%)
SHAREHOLER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Annovis Bio, Inc. of Class Action Lawsuit and Upcoming Deadline - ANVS

/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Annovis Bio, Inc. ("Annovis" or the "Company") (NYSE: ANVS) and...

ANVS : 8.85 (+2.79%)
CLASS ACTION UPDATE for ANVS, HNST and HYZN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / October 13, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders...

ANVS : 8.85 (+2.79%)
HNST : 3.07 (+1.99%)
HYZN : 4.15 (+2.22%)
LAWSUITS FILED AGAINST ANVS, EAR and HYZN - Jakubowitz Law Pursues Shareholders Claims

NEW YORK, NY / ACCESSWIRE / October 13, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who...

ANVS : 8.85 (+2.79%)
EAR : 1.0900 (+4.81%)
HYZN : 4.15 (+2.22%)
Kessler Topaz Meltzer & Check, LLP: Important Deadline Reminder for Annovis Bio, Inc. Investors in Securities Fraud Class Action Lawsuit

/PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against...

ANVS : 8.85 (+2.79%)
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of LIVE, ANVS and SAVA

NEW YORK, NY / ACCESSWIRE / October 12, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies....

LIVE : 34.50 (-2.65%)
ANVS : 8.85 (+2.79%)
SAVA : 25.35 (+1.16%)
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of KPLT, ANVS and WDH

NEW YORK, NY / ACCESSWIRE / October 12, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies....

ANVS : 8.85 (+2.79%)
KPLT : 1.1600 (+1.75%)
WDH : 1.0500 (-0.94%)
MONDAY DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Annovis Bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - ANVS

SAN DIEGO, CA / ACCESSWIRE / October 12, 2021 / Robbins Geller Rudman & Dowd LLP announces that purchasers of Annovis Bio, Inc. (NYSE:ANVS) securities between May 21, 2021 and July 28, 2021, both dates...

ANVS : 8.85 (+2.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Annovis Bio Inc. is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease, Parkinson's disease and Alzheimer's in Down Syndrome. Annovis Bio Inc. is headquartered in Berwyn, Pennsylvania.

See More

Key Turning Points

3rd Resistance Point 9.38
2nd Resistance Point 9.20
1st Resistance Point 8.90
Last Price 8.85
1st Support Level 8.42
2nd Support Level 8.24
3rd Support Level 7.94

See More

52-Week High 132.00
Fibonacci 61.8% 84.78
Fibonacci 50% 70.19
Fibonacci 38.2% 55.61
Last Price 8.85
52-Week Low 8.39

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar